NasdaqGM - Nasdaq Real Time Price USD

Sagimet Biosciences Inc. (SGMT)

Compare
4.5000 -0.0200 (-0.44%)
At close: November 21 at 4:00 PM EST
4.5400 +0.04 (+0.89%)
After hours: 7:34 PM EST
Loading Chart for SGMT
DELL
  • Previous Close 4.5200
  • Open 4.4600
  • Bid 3.4000 x 200
  • Ask 5.7200 x 100
  • Day's Range 4.2700 - 4.7600
  • 52 Week Range 2.3900 - 20.7100
  • Volume 500,464
  • Avg. Volume 1,485,980
  • Market Cap (intraday) 144.879M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3900
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 29.17

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

www.sagimet.com

8

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SGMT

View More

Performance Overview: SGMT

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SGMT
16.97%
S&P 500
24.72%

1-Year Return

SGMT
49.50%
S&P 500
30.82%

3-Year Return

SGMT
71.23%
S&P 500
31.53%

5-Year Return

SGMT
71.23%
S&P 500
31.53%

Compare To: SGMT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SGMT

View More

Valuation Measures

Annual
As of 11/21/2024
  • Market Cap

    144.88M

  • Enterprise Value

    -7.49M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    52.50

  • Price/Book (mrq)

    0.85

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.54%

  • Return on Equity (ttm)

    -29.32%

  • Revenue (ttm)

    2M

  • Net Income Avi to Common (ttm)

    -29.25M

  • Diluted EPS (ttm)

    -0.3900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    166.37M

  • Total Debt/Equity (mrq)

    0.08%

  • Levered Free Cash Flow (ttm)

    -14.4M

Research Analysis: SGMT

View More

Company Insights: SGMT

Research Reports: SGMT

View More

People Also Watch